These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 28573786

  • 1. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W, Yuan YC, Li MY, Kong W, Dong BJ, Chen YH, Zhang J, Xue W, Huang YR, Zhou LX, Huang JW.
    Zhonghua Zhong Liu Za Zhi; 2018 May 23; 40(5):384-389. PubMed ID: 29860767
    [Abstract] [Full Text] [Related]

  • 3. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P.
    BJU Int; 2016 Jan 23; 117(1):110-7. PubMed ID: 25252180
    [Abstract] [Full Text] [Related]

  • 4. Clinical Experience of Escalated Sunitinib Dose in Select Patients With Metastatic Renal Cell Carcinoma.
    Shi HZ, Tian J, Chen X, Wang D, Li CL.
    Clin Genitourin Cancer; 2017 Feb 23; 15(1):139-144. PubMed ID: 27338518
    [Abstract] [Full Text] [Related]

  • 5. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D, Gottfried M, Maimon N, Peer A, Neumann A, Hayat H, Kovel S, Sella A, Mermershtain W, Rouvinov K, Boursi B, Weitzen R, Berger R, Keizman D.
    Isr Med Assoc J; 2014 Jun 23; 16(6):347-51. PubMed ID: 25058995
    [Abstract] [Full Text] [Related]

  • 6. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Herman RM, Krzemieniecki K.
    Tumori; 2015 Jun 23; 101(5):555-9. PubMed ID: 26045121
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ, Lee JL, Park I, Park K, Ahn Y, Ahn JH, Lee DH, Ahn S, Song C, Hong JH, Kim CS, Ahn H.
    Chemotherapy; 2012 Jun 23; 58(6):468-74. PubMed ID: 23548259
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY.
    Cancer; 2012 Mar 01; 118(5):1252-9. PubMed ID: 21898376
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH, Kim HY, Kim HR, Sun JM, Lim HY, Lee HJ, Lee S, Bae WK, Rha SY, Korean Cancer Study Group, Genitourinary & Gynecology Cancer Committee.
    Eur J Cancer; 2014 Mar 01; 50(4):746-52. PubMed ID: 24332573
    [Abstract] [Full Text] [Related]

  • 10. Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.
    Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M.
    Eur J Cancer; 2016 Jul 01; 62():28-35. PubMed ID: 27192659
    [Abstract] [Full Text] [Related]

  • 11. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ.
    J Clin Oncol; 2009 Sep 01; 27(25):4068-75. PubMed ID: 19652072
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma.
    Li XS, Wu X, Zhao PJ, Huang LH, Song Y, Gong K, Shen C, Yu W, Song G, Zhao Z, Zhang Z, Zhang Q, Wang G, He ZS, Zhou LQ, Jin J.
    Chin Med J (Engl); 2011 Sep 01; 124(18):2920-4. PubMed ID: 22040503
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
    Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A.
    Eur Urol; 2011 Sep 01; 60(3):448-54. PubMed ID: 21612860
    [Abstract] [Full Text] [Related]

  • 17. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
    Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ.
    J Clin Oncol; 2017 Feb 20; 35(6):591-597. PubMed ID: 28199818
    [Abstract] [Full Text] [Related]

  • 18. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules.
    Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E.
    J Urol; 2014 Mar 20; 191(3):611-8. PubMed ID: 24018239
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X, Chi Z, Cui C, Si L, Li S, Tang B, Mao L, Lian B, Wang X, Yan X, Guo J.
    Oncotarget; 2016 May 10; 7(19):27044-54. PubMed ID: 26894858
    [Abstract] [Full Text] [Related]

  • 20. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
    Kim JH, Park I, Lee JL.
    Cancer Chemother Pharmacol; 2016 Aug 10; 78(2):325-32. PubMed ID: 27324136
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.